Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study - Yao, JC; Fazio, N; Singh, S (Lancet, 2016)
et al.